Cyclopharm Limited

ASX CYC.AX

Cyclopharm Limited EBIT for the year ending December 31, 2023: USD -2.71 M

Cyclopharm Limited EBIT is USD -2.71 M for the year ending December 31, 2023, a 36.84% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Cyclopharm Limited EBIT for the year ending December 31, 2022 was USD -4.28 M, a -19.06% change year over year.
  • Cyclopharm Limited EBIT for the year ending December 31, 2021 was USD -3.60 M, a 19.03% change year over year.
  • Cyclopharm Limited EBIT for the year ending December 31, 2020 was USD -4.44 M, a -24.73% change year over year.
  • Cyclopharm Limited EBIT for the year ending December 31, 2019 was USD -3.56 M, a -155.84% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
Loading...
ASX: CYC.AX

Cyclopharm Limited

CEO Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDM
IPO Date Jan. 17, 2007
Location Australia
Headquarters 1 The Crescent
Employees 87
Sector Health Care
Industries
Description

Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The Technegas segment offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. This segment also distributes third party products to the diagnostic imaging sector. The Molecular Imaging segment provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.

Similar companies

CGS.AX

Cogstate Limited

USD 0.68

3.05%

StockViz Staff

January 15, 2025

Any question? Send us an email